Gene Therapy: The “Key” to Dermatological disorders!
About Dermatological disorders
Dermatological disorders comprises of diseases of the skin, scalp, hair, and nails. Apart from being the largest organ in the body, the skin has a vital social function and relatively minor skin complaints often cause more anguish to people than other more serious medical disorders. Skin disease which might benefit from medical care is very common, affecting around one-third of the population at any one time.
With the exception of melanoma skin cancer, the majority of skin diseases are not life threatening. However it is the product of this morbidity multiplied by the high prevalence of these disorders which results in a large burden of disease in absolute terms. Small changes in health policy could have large health and financial implications simply because they affect so many people.
Gene Therapy: Role in Dermatology
Gene therapy is defined as the insertion of a desired gene (transgene) into recipient cells. It was traditionally considered a treatment modality for patients with life-threatening congenital defects of key metabolic functions or patients with late-stage malignancies. But the human genome project has provided us with the complete library of human DNA opening up endless opportunities for gene therapy in all medical and surgical specialties.
Cutasil (STP705) therapy is a topically applied formulation for delivery of the siRNAs to the wound site with accelerated wound repair yet with reduced scar formation. The safety and the healing effects of the treatment have been shown in both murine and swine excisional wound models.
Gene Therapy: The Market Scenario
There is a large iceberg of unmet dermatological need as previous surveys have suggested that a large quarter of the population has a skin problem which could benefit from medical care, yet about most of them do not seek medical help. But with increased public and professional awareness of effective treatment this submerged sector of the population is likely to surface and place heavy demands on the current system. Hence many companies such as Sirnaomics, Anges etc., are operating in the field of dermatologic disorders in the gene therapy domain as its demand is likely to increase over the next decade. Currently two companies viz., Anges & Sirnaomics are developing novel treatments for dermatological disorders. Moreover, three of the commonest and most costly skin diseases, viz skin cancer, atopic eczema and venous ulcers are becoming more common and are set to consume a higher proportion of scarce resources within future health services budgets. This has led to an increase in the global market opportunities for gene therapy with more companies focusing in this field.
DelveInsight’s Gene Therapy Reports
DelveInsight’s Gene Therapy Reports cover the entire gene therapy market insights for dermatological disorders including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight’s proprietary market and pipeline analytics which identifies the front runners in this therapeutic area. It also identifies the potential market movers and future regulatory landscape.